💸 The Tape

Decibel Cannabis (TSXV: DB) (OTCQB: DBCCF) became the latest Canadian producer to stake a claim in the United Kingdom on Thursday, licensing its General Admission and Standard Issue brands to Hilltop Leaf, a GMP-certified UK importer and distributor. Fifteen Decibel product lines and six Hilltop-branded lines launch in the fourth quarter, exported as finished, packaged medical products from Decibel's EU GMP facility in Chatham, Ontario. The two companies have worked together for several years; this formalizes a brand presence rather than a bulk-supply relationship, which is the more valuable end of the chain.

It's a sensible move for a company that just posted record $36 million quarterly revenue and completed a 15-to-1 consolidation. It's also a small piece of a much larger migration.

How the UK market actually works

The United Kingdom legalized medical cannabis on November 1, 2018, by moving cannabis-based products for medicinal use — CBPMs — into Schedule 2 of the Misuse of Drugs Regulations. Cannabis itself remains a Class B controlled drug. Recreational use is illegal, home cultivation is illegal, and smoking a prescribed product is prohibited; patients prescribed flower must vaporise it.

The structure is almost entirely private. Only doctors on the General Medical Council's Specialist Register can initiate a prescription for an unlicensed CBPM, which covers nearly every flower and extract product on the market, since only Sativex and Epidyolex hold full marketing authorisations. Unlicensed products are supplied under the "specials" exemption in the Human Medicines Regulations, which allows an unlicensed medicine when a licensed one can't meet a patient's clinical need. GPs can issue follow-up prescriptions under shared-care arrangements. The NHS is effectively closed: fewer than ten patients access CBPMs through the health service, because NICE won't recommend them without UK randomised controlled trial data that nobody has funded.

What that produced is a telehealth market. Patients consult specialists online, prescriptions are filled by a small number of licensed pharmacies, and product is delivered to the door. Prohibition Partners estimates eight platforms account for roughly 80% of all prescriptions, with Releaf, Curaleaf Clinic and CB1 Medical among the leaders. Advertising prescription medicines to the public is prohibited, which has shaped a market that grows through clinic marketing and word of mouth rather than brand campaigns — a point Decibel and Hilltop should keep in mind when they talk about "brand recognition."

Supply comes through two gates. The MHRA controls medicines regulation, including the import notification process for unlicensed products and GMP standards. The Home Office, through its Drugs and Firearms Licensing Unit, issues controlled-drug licences for import, with per-shipment licensing that the industry's own trade guides describe as a persistent cause of supply gaps. Domestic cultivation requires a Home Office licence and remains limited, so imports do the heavy lifting.

The numbers

The market is growing faster than anyone modeled. The UK imported 30,061 kilograms of CBPMs in 2025, more than double the prior year's 14,992 kilograms and the second consecutive year of doubling. The number of products available to patients rose from 374 in April 2025 to 818 by March 2026. Prohibition Partners puts the patient count on track to exceed 140,000 by year-end, up from roughly 100,000 a year earlier, with a base-case market value of about £345 million for 2026 and a path to £935 million and nearly 390,000 patients by 2030.

Canada is the supplier. Canadian exports to the UK rose 562% in 2025, from 2.58 tonnes to 17.07 tonnes, and now account for an estimated 70% to 80% of what's being prescribed. The UK has quietly become the most important export destination for Canadian LPs after Germany — and unlike Germany, there's no domestic cultivation tender, no pharmacy-only dispensing restriction on flower, and no reimbursement fight to win.

Who's moved in over the last year

Decibel is joining a crowded arrivals hall.

Curaleaf has the deepest position: Curaleaf Clinic is among the top prescribing platforms, and Curaleaf Laboratories signed a distribution agreement with Vericura on October 1 to expand UK manufacturing and distribution. The UK is part of why Curaleaf wants Aurora's European assets and why Cannara's export deal with Curaleaf International just grew 60%.

Aurora has been buying. Its defense of the at-the-market program in the Curaleaf fight explicitly cited "recent UK acquisitions" as the use of proceeds, and the UK is one of the international medical markets where Aurora's revenue is growing 17% year over year while Canadian medical shrinks.

Canopy Growth entered for the first time in September, supplying four Spectrum Therapeutics strains to GROW Group U.K. — a launch enabled by the EU GMP recertification at Kincardine the month before.

Cannara's expanded supply agreement with Curaleaf International routes Québec flower through Curaleaf's EU GMP processing into European markets, with the UK among them. And now Decibel arrives with brands rather than bulk, through a partner that already has prescriber and pharmacy relationships.

The pattern is consistent: an EU GMP-certified Canadian facility, a UK importer with a GMP certificate and a Home Office licence, and a private clinic channel that absorbs everything that clears customs.

What's next

Three things determine whether the next two years look like the last two.

The first is the ACMD review. The Advisory Council on the Misuse of Drugs opened a call for evidence in September 2025 on whether the 2018 rescheduling had its intended effect and what unintended consequences followed. Its final report is expected by the end of this year, and it's examining prescribing practices, private clinic governance, advertising and police handling. A market that scaled from zero to 140,000 patients in eight years almost entirely outside the NHS is going to get recommendations, and the clinics that have driven growth are the ones with the most to lose from tighter governance.

The second is supply-chain friction. Per-shipment Home Office import licences and MHRA notification requirements were designed for a market a tenth this size. Streamlining them is the single biggest operational unlock, and it's the one importers like Hilltop and GROW have been asking for. Domestic cultivation under Home Office licence is beginning to reach patients, which could ease the import bottleneck but would also compete with Canadian supply.

The third is NHS access, which is the long game. Without UK-generated trial evidence, NICE won't move, and without NICE, the market stays private-pay. The companies that fund that research — and the clinics with the patient registries to support it — will own the reimbursement channel when it opens.

For now, the UK is the clearest growth story in European cannabis: a legal, specialist-prescribed, privately funded market doubling every year, supplied by Canadian producers who finally have somewhere to send their flower. Decibel just made sure its brands are on the shelf when the next 40,000 patients arrive.

📈 Dog Walkers

$ACB ( ▼ 2.83% ) Beefs Up German Footprint

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) completed a multi-million-dollar expansion of its EU-GMP facility in Leuna, Germany, more than doubling expected annual flower output and rebranding the site Aurora Horizon. The newly built areas have received an expanded EU-GMP licence from the Saxony-Anhalt health authority, and the facility now runs Aurora's Canadian cultivation playbook — lighting, irrigation, harvest and post-harvest protocols — alongside proprietary genetics from the Aurora Coast R&D site in British Columbia.

The strategic point is in one phrase: Aurora is one of only three licensed domestic producers in Germany. Everyone else supplying the largest medical cannabis market outside North America is importing. Domestic EU-GMP cultivation inside the country means no import licence per shipment, no customs delay, no exposure to the Canadian export queue, and a cost base denominated in the same currency as the revenue. For a market where German imports more than doubled last year and where physicians are increasingly steering toward consistent, pharmacy-grade supply, in-country capacity is a structural advantage that imported flower can't replicate.

The timing is not subtle. Curaleaf's revised US$5.00 hostile bid is being formally reviewed by Aurora's Special Committee, and the entire argument of that bid is that Aurora's European assets are worth more inside Curaleaf's international platform than standing alone. Today's release is Aurora's rebuttal in concrete and steel: the European business just got bigger, cheaper to operate and harder to replace. Every incremental kilogram out of Leuna is a kilogram Curaleaf would otherwise have to buy from Cannara or ship from Canada.

Whether it changes the price is a different question. But it makes Aurora's sum-of-the-parts argument tangible at exactly the moment the committee has to put a number on it.

📺 Trade To Black

Governor Healey Says She'll Vote No on Cannabis Repeal | TDR Cannabis in 5

• Healey says no: Massachusetts Governor Maura Healey told WCVB she'd vote against the repeal, calling cannabis an important industry the state needs to keep legal.

• The polls agree: MassINC has the rollback losing 61-27, UNH has 71% opposed, and even the tightest August survey had it down 55-33.

• The stakes are real: Massachusetts has passed $10 billion in cumulative adult-use sales, and CCC Chair Chris Harding warns repeal would cost thousands of jobs, hundreds of businesses and billions in tax revenue.

• Watched beyond the state line: The SEIU is urging a no vote and a business-and-healthcare coalition is on TV, because MPP warns even a close result could fuel copycat repeals like the one surfacing in Maine.